Clinical trial · Observational
Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
Persistence Evaluation and Response Study for Immunotherapy Safety Tracking of Participants Who Receive an AvenCell CAR-T Cell Therapy
NCT07474051CI-TRIAL-00105623PERSISTenrolling by invitationClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of patients who participated in an AvenCell-sponsored clinical trial and received treatment with AvenCell's UniCAR or RevCAR platforms.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| AML (Acute Myelogenous Leukemia) | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
| B-cell Lymphoma | B-Cell Malignant Neoplasm | CURATED_BROADER | 0.80 |
| Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | ONTOLOGY_EXACT | 0.98 |
| Hematologic Malignancy | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Allo-QuadCAR01-T | Biological | — | UNRESOLVED |
| Allo-RevCAR01- T with Targeting Module R-TM123 | Biological | — | UNRESOLVED |
| UniCAR02-T (IMP) With Targeting Module TM123 | Biological | — | UNRESOLVED |
| UniCAR02-T-pPSMA | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- UniCAR02-T With Targeting Module TM123 (UC02-123-01)
- description
- All participants who previously received UniCAR02-T With Targeting Module TM123 in the parent study will be enrolled in this cohort for long-term follow-up.
- interventionNames
- Biological: UniCAR02-T (IMP) With Targeting Module TM123
- label
- UniCAR02-T With Targeting Module TMpPSMA (UC02-PSMA-01)
- description
- All participants who previously received UniCAR02-T With Targeting Module TMpPSMA in the parent study will be enrolled in this cohort for long-term follow-up.
- interventionNames
- Biological: UniCAR02-T-pPSMA
- label
- Allo-RevCAR01- T Targeting Module R-TM123 (AVC-201-01)
- description
- All participants who previously received Allo-RevCAR01- T Targeting Module R-TM123 in the parent study will be enrolled in this cohort for long-term follow-up.
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Participant who received an AVC-CAR-T cell therapy within an AVC-sponsored clinical trial. 2. Participant signed written informed consent for the AVC-PERSIST study. Exclusion Criteria: 1. Participant is unable to provide written informed consent. 2. Participant is unable to comply with study requirements in the eyes of the Investigator.
References
Publications (0)
Data not yet available
No reference posted for this study.